Please assess the completion status of the following clinical trial:

Trial Title: A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Documented/confirmed acute myelogenous leukemia (AML), except for acute promyelocytic leukemia~* Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2 in Part 1 and Part 2, participants enrolled in the extension/tail portion, Part 3 and Part 4 must have an ECOG performance status of 0 or 1~* All non-hematological adverse events of any prior chemotherapy, surgery or radiotherapy must have resolved to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Grade less than or equal to (\</=) 2 prior to starting therapy~* Adequate hepatic and renal function~* Willing to submit the blood sampling and bone marrow sampling required by protocol~Additional inclusion criteria for Parts 1-4 may apply.~Exclusion Criteria:~* Participants receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy within 14 days of first receipt of study drug, with the exception of hydroxyurea as defined in protocol~* History of allergic or toxic reactions attributed to cytarabine (Part 2) or history of allergic reactions to components of the formulated product~* Current evidence of central nervous system (CNS) leukemia~* Participants with severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study~* Participants with evidence of electrolyte imbalance greater than or equal to (\>/=) Grade 2 which cannot be corrected prior to study initiation~* Pregnant or breastfeeding women~* Human immunodeficiency virus (HIV) - positive participants receiving anti-retroviral therapy~* Participants who refuse to potentially receive blood products and/or have a hypersensitivity to blood products~Additional exclusion criteria for Parts 1-4 may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: RO5503781 (Type: EXPERIMENTAL): Participants will receive RO5503781 alone in escalating doses on Days 1 to 5 of each 28-day cycle until disease progression or unacceptable toxicity.
- Part 2: RO5503781 + Cytarabine (Type: EXPERIMENTAL): Participants will receive RO5503781 in escalating doses on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.
- Part3:RO5503781+Cytarabine+Anthracycline (Type: EXPERIMENTAL): Participants will receive RO5503781 on Days 1 to 5, cytarabine on Days 1 to 7, and anthracycline (daunorubicin or idarubicin) on Days 1 to 3 of each 28-day cycle until disease progression or unacceptable toxicity.
- Part 4: Optimized RO5503781 + Cytarabine (Type: EXPERIMENTAL): Participants will receive optimized RO5503781 formulation on Days 1 to 5 and cytarabine on Days 1 to 6 of each 28-day cycle until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete